Home > Insider Trading > Filing (0000903423-19-000271)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1679363	Morphic Holding Inc.	MORF	Pharmaceutical Preparations (2834)	X0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1131399	Plc Glaxosmithkline	980 Great West Road Brentford Middlesex X0 TW8 9GS		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-07-01	1,469,950	$0.00	1,469,950	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-07-01	830,489	$0.00	2,300,439	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2019-07-01	333,333	$15.00	2,633,772	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A preferred stock	Disposition	2019-07-01	1,469,950	$0.00	1,469,950	$0.00
Common Stock	Series B preferred stock	Disposition	2019-07-01	830,489	$0.00	830,489	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

S.R. One, Limited acquired 333,333 common shares of the Issuer in connection with the Issuer's initial public offering.
Each share of the Issuer's Series A Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in its initial public offering (the 'IPO") pursuant to a registration statement on Form S-1 (File No. 333-231837) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date..
Each share of the Issuer's Series B Preferred Stock automatically converted into one share of the Issuer's Common Stock on July 1, 2019 in connection with the closing of the Issuer's sale of its Common Stock in IPO pursuant to the Registration Statement, and had no expiration date.
The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").